Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
The trial of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor figitumumab in combination with carbo/taxol as first line therapy for advanced NSCLC was officially closed after it was determined that the experimental arm would not have a meaningful chance of appearing superior to standard carbo/taxol with a placebo ("futility analysis"). Dr. Sanborn had previously written about this trial after it was put on hold due to safety concerns with this combination.
Importantly, this agent is still being studied in combination with Tarceva, and that trial is still ongoing, as are trials with this agent in other cancers. It's not clear whether the safety concerns figitumumab in combination with chemo are specific to this one agent or whether other agents that inhibit the new target IGF-1R as a potentially important anti-cancer treatment will also show show safety problems and lack of efficacy in combination with chemo, nor do we know whether the issues are specific to carbo/taxol or could be a problem with other chemotherapy combinations.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Hi and welcome to GRACE. I'm sorry to know you are entering a new stage. I'm not about to comment just now but wanted to let you know I see your...
Edit to say, we can't give advice but we can comment with views and facts. :)
My first thought is to ask if she has been seen at a large...
Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...